Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
Ann-Lii Cheng, Gerardo Cornelio, Lin Shen, Timothy Price, Tsai-Sheng Yang, Ik Joo Chung, Guang-Hai Dai, Jen-Kou Lin, Atul Sharma, Kun-Huei Yeh, Brigette Ma, Adel Zaatar, Zhongzhen Guan, Nehal Masood, Vichien Srimuninnimit, Thomas Yau, Peter Gibbs, Xiuwen Wang, Dinesh Chandra Doval, Seung-Taek Oh Show all
Clinical Colorectal Cancer | CIG MEDIA GROUP, LP | Published : 2017
The trial was sponsored by Merck KGaA, Darmstadt, Germany. The authors thank the patients, investigators, coinvestigators, and study teams at each of the participating centers and at Merck KGaA, Darmstadt, Germany and Merck Serono, Mumbai, India. Medical writing assistance was provided by ClinicalThinking, Inc, Hamilton, NJ, and funded by Merck KGaA, Darmstadt, Germany.